Dumping Delaware Running to england

Its all about building a career. Paul did it, he came to AZ and now he is the President of the US. I imagine that an American is being groomed right now to run Europe.

 

Sure about that? Seems the infrastructure might be moving more toward Europe to better run the U.S. DB from the states had his chance at the plate. It's a new ball game.

 

Are you thinking that the Brits will run everything ? Thats not true, Matt Bell was picked as COO of MedImmune - he's from Philadelphia !

 

Hey Brennan sold his house in Delaware !

 

That is because he could smell the tar and see the barrels of feathers outside his door.

 

Why I bet they have three or four drugs ready to go already!!! Please, there will be nothing from there for a long time, if ever. Maybe we should become a building company instead of a Pharma company. We are better at building useful sites than discovering drugs. We built out Delaware site and even had to buy the Rollins building. Look how much that has paid off - we sold most of it, and Rollins was a HUGE loss! We built out Alderly Park and now sold it. Now we are spending HOW much for another new site??? WOW! Now that's innovation! GO, PASCAL!!!

 

It takes at least 8 years to go all the way through the approval process, even if they put something forward tomorrow. Don't hold your breath. This is smoke and mirrors to hold the stock price up for yet a while more until they either cash out or buy something really large. For companies of this size, buildings and such come out of the petty cash.

 

Hey bub, if it weren't for us Yanks, you'd be goose-stepping your way through Piccadilly Circus. And how come all you "blokes" wear suits that are 2 sizes too tight? And all the women dress like slags, even in the office. Your Christmas decorations are really hideous! Horlicks and Weetabix suck, and you can't get a decent drink in a pub even if you're willing to pay 20 bucks. Not to mention, you couldn't get a decent hamburger anywhere in your entire country. And people pick their noses in public and take showers roughly once a week. HAD ENOUGH? Because I've got more.

 

Oops! How could I forget TEETH? Don't you get free dental care over there? Why are English teeth a worldwide joke, Bloke?

 

"Operationally the company is a mess, and not a damn thing is being done to fix any of the problems, which leads me to believe that the management is in need of American assistance, once again. Will it be Pfizer or Merck? Pfizer, maybe, but I doubt Merck will fall for the same scam a second time. Can anyone say Head Fred?

Buying the rights from BMS for the diabetes franchise, to improve cash flow; skipping key and critical steps in the research and development process of pipeline drugs; and metaphorically putting fingers in the holes of the dike are all signs that AZ is being propped up and shopped around to the highest bidder. As a shareholder, I welcome change, and welcome a takeover."

Pfizer as a bidder? Interesting to look back at this post and see how right you were a few weeks back. Are you a shareholder, or mutual fund manager? Either way, kudos to you for figuring it out.

"Pfizer considers $100 billion bid for AstraZeneca: report

Sun, Apr 20, 2014, 1:33pm EDT

LONDON (Reuters) - U.S. pharmaceutical giant Pfizer (PFE) has approached British rival AstraZeneca (AZN.L) to propose a 60 billion pound ($101 billion) takeover, Britain's Sunday Times reported.

The paper cited senior investment bankers and industry sources saying that informal conversations about a deal had taken place between the two but that no talks were currently under way after AstraZeneca resisted the approach.

Pfizer and AstraZeneca both declined to comment on the report to Reuters.

AstraZeneca, Britain's second-biggest pharmaceuticals group, has been frequently touted as a potential takeover target as it wrestles with patents expiring on a number of best-selling drugs, leaving future growth uncertain.

Despite these problems, the company has attracted attention for experimental cancer drugs it is developing, which could be interesting for Pfizer which has faced patent losses of its own, notably anti-cholesterol treatment Lipitor.

The two firms are familiar with each other's products working together on projects such as the pioneering of a new kind of clinical trial for cancer drugs announced last week.

Pfizer could use cash it has accumulated through overseas subsidiaries, which if repatriated to the U.S. would be heavily taxed.

In the past Swiss drug firm Novartis (NOVN.VX) and larger British peer GlaxoSmithKline (GSK.L) have been mentioned as potential suitors, although GSK has publicly said it is not interested in making a large acquisition in recent years.

AstraZeneca, which announces first quarter results on Thursday, has a market valuation of around $80 billion, compared with Pfizer - valued at $193 billion, according to Thomson Reuters data.

Earnings at AstraZeneca fell 6 percent in the fourth quarter of 2013, and the drugmaker has said it expects them to keep falling in 2014 as generic competition to Nexium, its popular heartburn and ulcer drug, takes a big bite out of U.S. profits from late May.

AstraZeneca has suffered a dry period in drug discovery in recent years and badly needs to find new medicines to replace blockbusters such as Nexium and Crestor, a treatment for high cholesterol that will lose patent protection in a few years.

Pfizer's last big acquisition was in 2009, when it bought U.S. rival Wyeth for $68 billion.

($1 = 0.5949 British Pounds)

(Reporting by Stephen Eisenhammer; additional reporting by Ben Hirschler; editing by Jane Baird and William Hardy)"

 

"Resisted the approach"... Don't! STOP! Don't stop....

 

AZ is a painted tart lingering under a street light hoping to find a john

 

You Brits are going to be Pfired.
You lose again.